• Medicine Grade Raw Material CAS 56-92-8 Histamine Dihydrochloride Intermediate
  • Medicine Grade Raw Material CAS 56-92-8 Histamine Dihydrochloride Intermediate
  • Medicine Grade Raw Material CAS 56-92-8 Histamine Dihydrochloride Intermediate
  • Medicine Grade Raw Material CAS 56-92-8 Histamine Dihydrochloride Intermediate
  • Medicine Grade Raw Material CAS 56-92-8 Histamine Dihydrochloride Intermediate
  • Medicine Grade Raw Material CAS 56-92-8 Histamine Dihydrochloride Intermediate

Medicine Grade Raw Material CAS 56-92-8 Histamine Dihydrochloride Intermediate

Powder: Yes
Customized: Non-Customized
Certification: GMP, ISO 9001, USP, BP
Suitable for: Elderly, Children, Adult
State: Powder
Purity: >98%
Customization:
Diamond Member Since 2021

Suppliers with verified business licenses

Rating: 5.0/5
Manufacturer/Factory

Basic Info.

Model NO.
HNB-Histamine Dihydrochloride
CAS
56-92-8
Molecular Weight
184.064
Molecular Formula
C5h11cl2n3
Einecs
200-298-4
Transport Package
Aluminum Foil Bag/Drum
Specification
98%
Trademark
HNB BIOTECH
Origin
China-Xian

Product Description


Medicine Grade Raw Material CAS 56-92-8 Histamine Dihydrochloride IntermediateMedicine Grade Raw Material CAS 56-92-8 Histamine Dihydrochloride Intermediate
Medicine Grade Raw Material cas 56-92-8 Histamine Dihydrochloride intermediate 
Medicine Grade Raw Material CAS 56-92-8 Histamine Dihydrochloride Intermediate

Production Introduction:
 

Histamine dihydrochloride is a salt of histamine which is used as a drug for the prevention of relapse in patients diagnosed with acute myeloid leukemia.

It is a FDA-approved active ingredient for topical analgesic use and is available in such products as Australian Dream Cream, which is used for the temporary relief of minor aches and pains of muscles and joints associated with arthritis, simple backache, bruises, sprains, and strains.

 

 


Application:
 

Histamine dihydrochloride is administered in conjunction with low doses of the immune-activating cytokine interleukin-2 (IL-2) in the post-remission phase of AML, i.e. when patients have completed the initial chemotherapy. This combination has been reported to significantly reduce the risk of relapse in AML.The effect is particularly pronounced in patients in their first remission who are below the age of 60.

The combination of histamine dihydrochloride and interleukin-2 was approved for use in AML patients within the European Union in October 2008 and will be marketed in the EU by the Swedish pharmaceutical company Meda. The drug is also available through a named patient program in several other countries (excluding the US).


Medicine Grade Raw Material CAS 56-92-8 Histamine Dihydrochloride Intermediate
Medicine Grade Raw Material CAS 56-92-8 Histamine Dihydrochloride Intermediate
Medicine Grade Raw Material CAS 56-92-8 Histamine Dihydrochloride IntermediateMedicine Grade Raw Material CAS 56-92-8 Histamine Dihydrochloride IntermediateMedicine Grade Raw Material CAS 56-92-8 Histamine Dihydrochloride IntermediateMedicine Grade Raw Material CAS 56-92-8 Histamine Dihydrochloride IntermediateMedicine Grade Raw Material CAS 56-92-8 Histamine Dihydrochloride IntermediateMedicine Grade Raw Material CAS 56-92-8 Histamine Dihydrochloride IntermediateMedicine Grade Raw Material CAS 56-92-8 Histamine Dihydrochloride Intermediate
Medicine Grade Raw Material CAS 56-92-8 Histamine Dihydrochloride Intermediate

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now